Wintrust Investments LLC boosted its position in Zoetis Inc (NYSE:ZTS) by 64.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,817 shares of the company’s stock after purchasing an additional 1,490 shares during the quarter. Wintrust Investments LLC’s holdings in Zoetis were worth $433,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of ZTS. Dimensional Fund Advisors LP increased its stake in Zoetis by 2.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,425,455 shares of the company’s stock valued at $121,929,000 after buying an additional 39,319 shares during the period. Raymond James & Associates increased its stake in Zoetis by 5.9% during the 1st quarter. Raymond James & Associates now owns 862,600 shares of the company’s stock valued at $86,839,000 after buying an additional 48,065 shares during the period. WealthPLAN Partners LLC increased its stake in Zoetis by 6.9% during the 1st quarter. WealthPLAN Partners LLC now owns 4,162 shares of the company’s stock valued at $424,000 after buying an additional 268 shares during the period. Decatur Capital Management Inc. acquired a new position in Zoetis during the 1st quarter valued at about $5,462,000. Finally, Greenleaf Trust increased its stake in Zoetis by 9.0% during the 2nd quarter. Greenleaf Trust now owns 3,811 shares of the company’s stock valued at $433,000 after buying an additional 315 shares during the period. Hedge funds and other institutional investors own 90.42% of the company’s stock.

Several equities analysts have commented on ZTS shares. Gabelli cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $108.00 target price on the stock. in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Stifel Nicolaus raised their target price on shares of Zoetis from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and raised their target price for the company from $111.00 to $120.00 in a research note on Monday, July 1st. They noted that the move was a valuation call. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Finally, Barclays raised their target price on shares of Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Zoetis currently has a consensus rating of “Buy” and an average target price of $115.13.

Shares of ZTS traded up $1.81 during mid-day trading on Wednesday, hitting $127.86. The company’s stock had a trading volume of 33,144 shares, compared to its average volume of 2,001,309. The firm has a 50-day moving average price of $117.56 and a 200 day moving average price of $104.85. The stock has a market capitalization of $59.87 billion, a price-to-earnings ratio of 40.83, a PEG ratio of 3.17 and a beta of 0.92. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $128.41.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The business’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.77 EPS. As a group, equities analysts anticipate that Zoetis Inc will post 3.57 EPS for the current fiscal year.

In other news, EVP Clinton A. Jr. Lewis sold 6,123 shares of Zoetis stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $109.79, for a total value of $672,244.17. Following the transaction, the executive vice president now directly owns 49,369 shares of the company’s stock, valued at $5,420,222.51. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,900 shares of Zoetis stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $110.58, for a total transaction of $210,102.00. Following the completion of the transaction, the director now directly owns 2,816 shares in the company, valued at $311,393.28. The disclosure for this sale can be found here. Insiders sold a total of 43,432 shares of company stock worth $5,083,246 in the last ninety days. Corporate insiders own 0.29% of the company’s stock.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: Bond

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.